FlandersBio on Twitter

Follow us on Twitter

Archive for March 2014 - News

Archive for March 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

MDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test

28.03.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the Molecular and Clinical Genetics Panel of the United States Food and Drug Administration's (FDA) Medical Devices Advisory Committee strongly endorsed approval of Cologuard(TM). The Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Cologuard incorporates one of MDxHealth's epigenetic biomarkers and methylation specific PCR (MSP) technology, which was licensed to Exact Sciences in July 2010. read more

Complix to Present at BioCapital Europe 2014

26.03.2014

Complix, a biopharmaceutical company focused on the discovery and development of Cell Penetrating Alphabodies™ (CPABs), a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present tomorrow at BioCapital Europe 2014 in Amsterdam, the Netherlands (March 27th). Details of the presentation are listed below. read more

Cardio3 BioSciences’ cell therapy approach for cardiac repair recognized in Nature Reviews Cardiology

26.03.2014

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces the referencing in the journal Nature Reviews Cardiology of lineage-specified cardiac progenitor (Cardiopoietic) cells as a next generation advancement in the science of cardiac regeneration. read more

Euronext Amsterdam to become Market of Reference for Galapagos

21.03.2014

Galapagos NV (Euronext: GLPG) announced today that the market of reference will change from Euronext Brussels to Euronext Amsterdam, effective as of 28 March 2014. The change of market of reference means that orders in Galapagos' securities will be gathered and centrally administered in the single order book in Euronext Amsterdam. read more

New discoveries place lack of energy at the basis of Parkinson’s Disease

21.03.2014

Neuroscientists Vanessa Moraïs and Bart De Strooper from VIB and KU Leuven have demonstrated how a defect in the gene Pink1 results in Parkinson’s disease. By mapping this process at a molecular level, they have provided the ultimate proof that a deficient energy production process in cells can result in Parkinson’s disease. These insights are so revolutionary that they have been published in the leading journal Science. read more

Aratana and Advaxis Enter Exclusive Global Licensing Agreement

21.03.2014

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma. read more

Cryo-Save Group N.V. - EGM resolutions: Mr Frédéric Amar appointed Executive Director and CEO

20.03.2014

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that all proposed resolutions at today's EGM were passed. read more

CARDIO3 BIOSCIENCES REPORTS 2013 FINANCIAL RESULTS AND BUSINESS UPDATE

19.03.2014

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces a business update and its consolidated financial results for the twelve-month period ending 31 December 2013 prepared in accordance with IFRS as endorsed by the European Union. read more

ThromboGenics' JETREA Approved in Switzerland for the Treatment of Vitreomacular Traction

19.03.2014

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Swissmedic has approved JETREA® (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. ThromboGenics' partner Alcon holds the commercialization rights to JETREA® outside the US and will be responsible for the launch of the drug in Switzerland. read more

Cryo-Save-new Board, acquisition of Salveo + strategic review after turnaround will bring a profitable future

18.03.2014

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2013. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print